Peptide Receptor Radionuclide Therapy Using (177) Lu-DOTATATE in Advanced Neuroendocrine Tumors (NETs) in a Limited-Resource Environment

Background  This study was conducted to evaluate the clinical efficacy and safety of peptide receptor radionuclide therapy (PRRT) using (177) Lu-DOTA0-Tyr3-octreotate (DOTATATE) in patients with neuroendocrine tumors (NETs). Methods  Sixteen patients with pathologically verified NETs including eight...

Descripción completa

Detalles Bibliográficos
Autores principales: Kalantarhormozi, Mohammadreza, Hassanzadeh, Samaneh, Rekabpour, Seyed Javad, Ravanbod, Mohammad Reza, Jafari, Esmail, Amini, AbdulLatif, Dadgar, Habibollah, Mahmoudpour, Mehdi, Nabipour, Iraj, Jokar, Narges, Assadi, Majid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Pvt. Ltd. 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436514/
https://www.ncbi.nlm.nih.gov/pubmed/36060085
http://dx.doi.org/10.1055/s-0042-1755412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9436514/
https://www.ncbi.nlm.nih.gov/pubmed/36060085
http://dx.doi.org/10.1055/s-0042-1755412

Ejemplares similares